Vivo Capital
Multi-Strategy- Manager
- Vivo Capital
- Quarter
- Q2 2026
- Filed
- 2026-08-14
- 13F value
- $1.10B
- Positions
- 47
- CIK
- 0001674712
| # | # Shares | Source | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | Trevi Therapeutics IncTRVIHISTORY | 8.68% | — | $95.0M | 5,094,668 | — | 3.58% | 13F |
| 2 | Praxis Precision MedicinesPRAXHISTORY | 8.29% | (20.0%) | $90.8M | 271,116 | (67,779) | 0.97% | 13F |
| 3 | Erasca IncERASHISTORY | 6.90% | (66.0%) | $75.6M | 4,127,412 | (8,024,068) | 1.18% | 13F |
| 4 | Arrivent BioPharma IncAVBPHISTORY | 5.34% | +89.9% | $58.4M | 1,682,097 | +796,181 | 3.41% | 13F |
| 5 | Abivax SA - ADRABVXHISTORY | 5.05% | +73.2% | $55.3M | 414,899 | +175,360 | 0.53% | 13F |
| 6 | Tango Therapeutics IncTNGXHISTORY | 3.94% | (36.0%) | $43.1M | 1,379,769 | (775,011) | 0.82% | 13F |
| 7 | Corvus Pharmaceuticals IncCRVSHISTORY | 3.83% | — | $41.9M | 2,805,816 | — | 3.34% | 13F |
| 8 | Bright Minds Biosciences IncDRUGHISTORY | 3.57% | — | $39.1M | 557,172 | — | 12.32% | 13F |
| 9 | Sinovac Biotech Ltd.SVAHISTORY | 3.49% | — | $38.2M | 5,903,000 | — | 8.21% | 13F |
| 10 | Tenax Therapeutics IncTENXHISTORY | 3.32% | +1,100.0% | $36.4M | 2,500,000 | +2,291,667 | 6.68% | 13F |
| 11 | Aclaris Therapeutics, Inc.ACRSHISTORY | 3.23% | +0.4% | $35.4M | 6,694,637 | +27,971 | 4.55% | 13F |
| 12 | Dyne Therapeutics IncDYNHISTORY | 3.16% | — | $34.6M | 1,557,466 | — | 0.83% | 13F |
| 13 | Dianthus Therapeutics IncDNTHHISTORY | 3.15% | — | $34.5M | 353,998 | — | 0.63% | 13F |
| 14 | Alto Neuroscience IncANROHISTORY | 2.91% | +16.7% | $31.9M | 1,208,858 | +173,307 | 3.08% | 13F |
| 15 | DBV Technologies SADBVTHISTORY | 2.76% | (30.8%) | $30.3M | 1,844,758 | (822,811) | 0.62% | 13F |
| 16 | SAB Biotherapeutics IncSABSHISTORY | 2.60% | (36.1%) | $28.5M | 7,299,909 | (4,120,091) | 8.02% | 13F |
| 17 | Moonlake ImmunotherapeuticsMLTXHISTORY | 2.49% | +40.0% | $27.3M | 1,400,000 | +400,000 | 1.64% | 13F |
| 18 | LB Pharmaceuticals IncLBRXHISTORY | 2.37% | — | $26.0M | 800,000 | — | 2.48% | 13F |
| 19 | Minerva Neurosciences IncNERVHISTORY | 2.19% | — | $24.0M | 4,322,747 | — | 9.05% | 13F |
| 20 | Design Therapeutics IncDSGNHISTORY | 2.13% | — | $23.3M | 1,612,903 | — | 2.58% | 13F |
| 21 | Oric Pharmaceuticals IncORICHISTORY | 1.83% | — | $20.0M | 1,848,786 | — | 1.78% | 13F |
| 22 | CAMP4 Therapeutics CorporationCAMPHISTORY | 1.69% | — | $18.6M | 4,246,568 | — | 6.77% | 13F |
| 23 | Faeth Therapeutics IncFTHHISTORY | 1.65% | — | $18.1M | 722,020 | — | 2.79% | 13F |
| 24 | Achieve Life Sciences Inc.ACHVHISTORY | 1.64% | NEW | $18.0M | 2,751,032 | +2,751,032 | 2.67% | 13F |
| 25 | Compass Therapeutics IncCMPXHISTORY | 1.55% | (18.7%) | $17.0M | 7,757,060 | (1,788,406) | 4.31% | 13F |
| 26 | AN2 Therapeutics IncANTXHISTORY | 1.39% | — | $15.3M | 3,153,640 | — | 8.36% | 13F |
| 27 | Editas Medicine IncEDITHISTORY | 1.05% | NEW | $11.5M | 3,555,250 | +3,555,250 | 2.31% | 13F |
| 28 | Geron CorpGERNHISTORY | 1.01% | — | $11.1M | 8,671,797 | — | 1.35% | 13F |
| 29 | Odyssey Therapeutics IncODTXHISTORY | 0.98% | NEW | $10.8M | 575,000 | +575,000 | 1.20% | 13F |
| 30 | Eupraxia Pharmaceuticals IncEPRXHISTORY | 0.81% | — | $8.9M | 1,350,000 | — | 3.79% | 13F |
| 31 | Onkure Therapeutics IncOKURHISTORY | 0.80% | — | $8.8M | 1,927,710 | — | 4.76% | 13F |
| 32 | Olema Pharmaceuticals IncOLMAHISTORY | 0.77% | — | $8.4M | 671,843 | — | 0.77% | 13F |
| 33 | Monopar Therapeutics IncMNPRHISTORY | 0.77% | — | $8.4M | 90,500 | — | 1.35% | 13F |
| 34 | Aura Biosciences IncAURAHISTORY | 0.76% | NEW | $8.3M | 1,166,667 | +1,166,667 | 1.12% | 13F |
| 35 | Surrozen IncSRZNHISTORY | 0.62% | — | $6.7M | 260,000 | — | 2.21% | 13F |
| 36 | ALX Oncology Holdings IncALXOHISTORY | 0.60% | — | $6.6M | 3,184,713 | — | 2.30% | 13F |
| 37 | Satellos Bioscience IncMSLEHISTORY | 0.58% | — | $6.3M | 813,666 | — | 5.26% | 13F |
| 38 | Avalo Therapeutics IncAVTXHISTORY | 0.46% | NEW | $5.1M | 275,000 | +275,000 | 0.51% | 13F |
| 39 | Pepgen IncPEPGHISTORY | 0.38% | — | $4.2M | 2,325,000 | — | 3.36% | 13F |
| 40 | Valneva SEVALNHISTORY | 0.36% | NEW | $4.0M | 763,199 | +763,199 | 0.44% | 13F |
| 41 | Sera Prognostics IncSERAHISTORY | 0.27% | — | $3.0M | 1,650,440 | — | 5.63% | 13F |
| 42 | Unicycive TherapeuticsUNCYHISTORY | 0.24% | (69.3%) | $2.6M | 550,000 | (1,239,916) | 1.97% | 13F |
| 43 | Instil Bio IncTILHISTORY | 0.21% | — | $2.3M | 292,743 | — | 4.32% | 13F |
| 44 | InMed Pharmaceuticals IncINMHISTORY | 0.11% | NEW | $1.2M | 798,377 | +798,377 | 14.53% | 13F |
| 45 | Bolt Biotherapeutics IncBOLTHISTORY | 0.03% | — | $0.3M | 72,414 | — | 3.76% | 13F |
| 46 | Pasithea Therapeutics CorpKTTAHISTORY | 0.02% | (77.8%) | $0.2M | 465,471 | (1,634,529) | 1.39% | 13F |
| 47 | Precision Biosciences IncDTILHISTORY | <0.01% | — | $<0.1M | 4,675 | — | 0.02% | 13F |
Positions are from the latest 13F-HR (period end 2026-06-30). Weights are calculated: position value ÷ the 13F book. Schedule 13D/13G stakes are merged in when present (shares and percent of class, no dollar value). Chg Shares and % Chg compare with the adjacent prior quarter's 13F only. % Out is either calculated (position shares ÷ issuer shares outstanding from the issuer's XBRL cover page; weighted-average basic shares as a fallback) or reported (percent of class on a Schedule 13D/13G newer than the 13F period) — hover a value for its source and date. Unavailable figures show “—”, never an estimate. Methodology